ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,763,962 | -22.7% | 49,480 | 0.0% | 0.01% | -18.8% |
| Q2 2023 | $2,282,512 | +2.0% | 49,480 | -18.4% | 0.02% | 0.0% |
| Q1 2023 | $2,237,989 | -2.4% | 60,635 | +22.5% | 0.02% | +6.7% |
| Q4 2022 | $2,292,301 | +11.9% | 49,480 | 0.0% | 0.02% | +7.1% |
| Q3 2022 | $2,049,000 | -30.6% | 49,480 | 0.0% | 0.01% | -41.7% |
| Q2 2022 | $2,952,000 | -17.8% | 49,480 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $3,593,000 | -13.7% | 49,480 | 0.0% | 0.02% | -11.1% |
| Q4 2021 | $4,161,000 | -6.7% | 49,480 | 0.0% | 0.03% | -10.0% |
| Q3 2021 | $4,462,000 | -5.4% | 49,480 | 0.0% | 0.03% | -6.2% |
| Q2 2021 | $4,718,000 | -64.0% | 49,480 | -49.7% | 0.03% | -70.6% |
| Q1 2021 | $13,088,000 | -3.9% | 98,429 | 0.0% | 0.11% | +0.9% |
| Q4 2020 | $13,626,000 | +168.6% | 98,429 | -19.0% | 0.11% | +92.9% |
| Q1 2020 | $5,073,000 | -2.2% | 121,500 | 0.0% | 0.06% | 0.0% |
| Q4 2019 | $5,189,000 | -13.7% | 121,500 | -13.5% | 0.06% | -30.0% |
| Q3 2019 | $6,011,000 | -24.2% | 140,500 | +12.0% | 0.08% | -19.2% |
| Q2 2019 | $7,934,000 | -1.0% | 125,500 | +8.7% | 0.10% | -2.9% |
| Q1 2019 | $8,011,000 | +59.5% | 115,500 | 0.0% | 0.10% | +32.5% |
| Q4 2018 | $5,022,000 | -41.8% | 115,500 | +2.1% | 0.08% | -33.0% |
| Q3 2018 | $8,634,000 | +32.1% | 113,100 | +33.1% | 0.12% | +11.7% |
| Q2 2018 | $6,534,000 | +40.8% | 85,000 | -6.6% | 0.10% | +30.4% |
| Q1 2018 | $4,640,000 | +35.2% | 91,000 | +23.0% | 0.08% | +33.9% |
| Q4 2017 | $3,432,000 | +7.4% | 74,000 | +23.3% | 0.06% | +5.4% |
| Q3 2017 | $3,196,000 | -14.2% | 60,000 | 0.0% | 0.06% | -20.0% |
| Q2 2017 | $3,727,000 | -20.3% | 60,000 | -13.0% | 0.07% | -23.1% |
| Q1 2017 | $4,677,000 | -13.6% | 69,000 | -10.4% | 0.09% | -26.6% |
| Q4 2016 | $5,414,000 | +52.6% | 77,000 | +54.0% | 0.12% | +45.9% |
| Q3 2016 | $3,547,000 | +20.9% | 50,000 | -16.7% | 0.08% | +11.8% |
| Q2 2016 | $2,935,000 | -27.2% | 60,000 | -6.2% | 0.08% | -24.8% |
| Q1 2016 | $4,030,000 | +18.6% | 64,000 | +111.4% | 0.10% | +11.0% |
| Q4 2015 | $3,397,000 | +34.2% | 30,280 | +15.2% | 0.09% | +46.8% |
| Q3 2015 | $2,531,000 | -31.3% | 26,280 | -27.0% | 0.06% | -19.5% |
| Q2 2015 | $3,686,000 | -1.1% | 36,000 | -40.0% | 0.08% | +2.7% |
| Q1 2015 | $3,726,000 | – | 60,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |